Registration for a live webinar on 'Rare disease clinical trials: challenges and best practices' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Lecture contents
- Allergy and asthma
- Action of omalizumab
- Clinical trial for omalizumab
- Results of clinical trial
- Secondary outcomes
- Omalizumab licence
- Practical considerations
- Expanded dose table
- What do guidelines say about omalizumab?
- Severe asthma
- Current situation
- SMC decision
- NICE final appraisal determination (1)
- RBH difficult asthma protocol
- NICE final appraisal determination (2)
- Monitoring
- Evidence from Joint task force
- Summary of recommendations
- Summary of timing of adverse reactions
- Monitoring after injections
- NICE vs. SMC
- Median daily OCS use
- Median AQLQ total scores
- Median FEV1
- Current UK practice
- A retrospective analysis of omalizumab treatment
- Objectives
- Eligibility
- Patient demographics
- OCS daily dose
- Percentage stopping or reducing OCS use
- Asthma exacerbations pre and post OMB
- Quality of life pre and post OMB
- NHS resource use - hospitalisations
- NHS resource use - no. days hospitalised
- Lung function pre and post OMB initiation
- How long to treat?
- Research evidence
- FEV1 after omalizumab withdrawal
- Asthma after stopping omalizumab
- Asthma medication changed after omalizumab
- Conclusions
Topics Covered
- Anti-IgE therapy for asthma
- Allergy can be associated with severe asthma
- Omalizumab, a monoclonal anti-IgE, is the first targeted biological therapy for severe asthma with good clinical efficacy
- Patient selection, drug administration and length of treatment are discussed
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Menzies-Gow, A. (2013, January 17). Anti-IgE therapy for asthma [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 16, 2024, from https://doi.org/10.69645/XXGZ7037.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Andrew Menzies-Gow has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
Hello.
My name is Andrew Menzies-Gow.
I'm a consultant
respiratory physician
at the Royal Brompton Hospital.
I'm going to talk to you about
Anti-IgE therapy for asthma.
0:11
During my talk, I'll
cover the evidence
for omalizumab
therapy in asthma,
the current situation
within the United Kingdom,
and evidence from
real life studies.
An important question that
I'm often asked about
omalizumab therapy is,
how long patients should
start it and stay on it,
if it is of benefit?
0:32
We know that the majority of
asthmatics attacks are also atopics.
They have positive skin tests
for common aeroallergens.
In large surveys of asthma
from across the world,
up to 90% of asthma occurs
in association with allergy.
We also know that allergen
specific IgE can both
initiate and maintain the
inflammatory response
which is characteristic of
asthma and associated with
Th2 inflammation and then
infiltration of eosinophils
into the airway mucosa.
Therefore, IgE becomes
a very logical target
for asthma therapy.
Whenever we think about
blocking part of
the immune system,
we need to be certain
that it's going to have
relatively few side
effects and not cause
a catastrophic failure
of the immune system.
We know that the
physiological root of IgE
appears to be fighting
parasitic infections,
primarily anti-nematode
infections.
Therefore, certainly
in the western world,
blocking IgE is likely to
prevent allergic inflammation
with no significant impact on
the immune system's ability
to fight infections.
1:34
Anti-IgE is a
monoclonal antibody
that's injected subcutaneously.
It finds its way to the serum
where it binds to free IgE
and produces multimers
that are removed
by the reticular
endothelial system.
It prevents IgE binding to
the surface of mast cells,
so it very quickly
depletes pre-serum IgE,
but it can take up to
eight weeks before
the levels of IgE on the
surface of mast cells
and basophils start to decrease,
which is why the treatment takes
at least 8 to 16 weeks before
we see any improvement
in asthma symptoms.
Importantly, anti-IgE
does not bind to IgE
that's already on the surface
of mast cells or basophils.
Therefore, it can't induce
an anaphylactic reaction
by directly cross-linking IgE on
the surface of mast
cells and basophils.